Lead sponsor
MapLight Therapeutics
2 Alzheimer’s disease and related dementias trials led. Source: ClinicalTrials.gov, as of July 21, 2026.
2
Trials led
2
Ongoing
510
Total enrollment
38
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 2
2
Trials by status
Recruiting
2
Trials led
TrialEligibility highlightPhaseStatusEnrollment
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease PsychosisAlzheimer's diseasePh 2Recruiting300
An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease PsychosisAge 55-91Ph 2Recruiting210